Literature DB >> 1728898

Sinusitis in infants and children.

E R Wald1.   

Abstract

The major clinical problem in considering a diagnosis of sinusitis is differentiating uncomplicated upper respiratory tract infection from a secondary bacterial infection of the paranasal sinuses that may benefit from antimicrobial therapy. A diagnosis of sinusitis is suggested by presentation with protracted upper respiratory tract symptoms or a cold that is more severe than usual with fever and purulent nasal discharge. Confirmatory tests of sinus disease are transillumination (useful in adolescents if interpretation is confined to the extremes--normal or absent); radiographic findings of opacification, mucous membrane thickening, or an air-fluid level; and sinus aspiration (indicated for severe pain, clinical failures, or complicated disease). When clinical signs and symptoms are accompanied by abnormal radiographic findings, bacteria in high colony count are recovered from the maxillary sinus aspirate in 70% of patients. The common bacterial species recovered from children with acute maxillary sinusitis are Streptococcus pneumoniae, Moraxella (Branhamella) catarrhalis, and Hemophilus influenzae.

Entities:  

Mesh:

Year:  1992        PMID: 1728898     DOI: 10.1177/00034894921010s108

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol Suppl        ISSN: 0096-8056


  3 in total

1.  Diagnosis and management of acute rhinosinusitis in children.

Authors:  Gualtiero Leo; Francesca Mori; Cristoforo Incorvaia; Simona Barni; Elio Novembre
Journal:  Curr Allergy Asthma Rep       Date:  2009-05       Impact factor: 4.806

Review 2.  Prevention of recurrent respiratory tract infections in children using a ribosomal immunotherapeutic agent: a clinical review.

Authors:  Jean Bousquet; Alessandro Fiocchi
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 3.  [Current management of acute pediatric rhinosinusitis in France].

Authors:  J-M Klossek; B Quinet; E Bingen; M François; J Gaudelus; S Larnaudie; F Liard; Y Péan; G Roger; O Reveillaud; E Serrano
Journal:  Med Mal Infect       Date:  2007-02-21       Impact factor: 2.152

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.